Compare HUYA & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUYA | SENS |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 572.2M | 476.9M |
| IPO Year | 2018 | 2014 |
| Metric | HUYA | SENS |
|---|---|---|
| Price | $2.32 | $8.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $3.52 | ★ $13.67 |
| AVG Volume (30 Days) | ★ 795.1K | 670.0K |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | $10.15 | $82.21 |
| Revenue Next Year | $7.09 | $55.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $2.02 | $0.41 |
| 52 Week High | $4.93 | $10.64 |
| Indicator | HUYA | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 45.48 |
| Support Level | $2.05 | $8.45 |
| Resistance Level | $2.55 | $10.07 |
| Average True Range (ATR) | 0.07 | 0.47 |
| MACD | 0.00 | -0.18 |
| Stochastic Oscillator | 58.97 | 16.13 |
Huya officially became independent in 2016 and is headquartered in Guangzhou. It operates a live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. Huya is a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power, as of the end of 2025.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.